KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Research & Development (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Research & Development for 16 consecutive years, with $192.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 10.9% year-over-year to $192.4 million, compared with a TTM value of $921.9 million through Dec 2025, up 23.39%, and an annual FY2025 reading of $921.9 million, up 23.39% over the prior year.
  • Research & Development was $192.4 million for Q4 2025 at Biomarin Pharmaceutical, down from $409.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $409.5 million in Q3 2025 and bottomed at $148.7 million in Q1 2021.
  • Average Research & Development over 5 years is $184.7 million, with a median of $172.3 million recorded in 2022.
  • Peak annual rise in Research & Development hit 121.46% in 2025, while the deepest fall reached 22.57% in 2025.
  • Year by year, Research & Development stood at $161.1 million in 2021, then increased by 7.24% to $172.8 million in 2022, then rose by 19.39% to $206.2 million in 2023, then decreased by 15.87% to $173.5 million in 2024, then rose by 10.9% to $192.4 million in 2025.
  • Business Quant data shows Research & Development for BMRN at $192.4 million in Q4 2025, $409.5 million in Q3 2025, and $161.3 million in Q2 2025.